

## SLEEP AND NEUROLOGICAL DISORDERS

## Familial Kleine-Levin Syndrome: A Specific Entity?

Quang Tuan Remy Nguyen, MD<sup>1</sup>; Elisabeth Groos, MD<sup>1</sup>; Laurène Leclair-Visonneau, MD<sup>2</sup>; Christelle Monaca-Charley, MD, PhD<sup>3</sup>; Tom Rico, BS<sup>4</sup>; Neal Farber, PhD<sup>5</sup>; Emmanuel Mignot, MD, PhD<sup>4</sup>; Isabelle Arnulf, MD, PhD<sup>1</sup>

<sup>1</sup>National Reference Center for Narcolepsy, Idiopathic Hypersomnia and Kleine–Levin Syndrome, Sleep Disorders Unit and Hospital-University Institute of Neuroscience, Pitié-Salpêtrière Hospital (APHP), Pierre and Marie Curie University, Paris, France; <sup>2</sup>Regional Competence Center for Narcolepsy, Idiopathic Hypersomnia and Kleine–Levin Syndrome, Laennec University Hospital, Nantes, France; <sup>3</sup>Regional Competence Center for Narcolepsy, Idiopathic Hypersomnia and Kleine–Levin Syndrome, Salengro University Hospital, Lille, France; <sup>4</sup>Center for Sleep Sciences and Medicine, Stanford University, Palo Alto, CA; <sup>5</sup>Kleine-Levin Syndrome Foundation, Boston, MA

**Study Objectives:** Kleine-Levin syndrome (KLS) is a rare, mostly sporadic disorder, characterized by intermittent episodes of hypersomnia plus cognitive and behavior disorders. Although its cause is unknown, multiplex families have been described. We contrasted the clinical and biological features of familial versus sporadic KLS.

**Methods:** Two samples of patients with KLS from the United States and France (n = 260) were studied using clinical interviews and human leukocyte antigen (HLA) genotyping. A multiplex family contained two or more first- or second-degree affected relatives (familial cases).

**Results:** Twenty-one patients from 10 multiplex families (siblings: n = 12, including two pairs of monozygotic twins; parent-child: n = 4; cousins: n = 2; uncle-nephews: n = 3) and 239 patients with sporadic KLS were identified, yielding to 4% multiplex families and 8% familial cases. The simplex and multiplex families did not differ for autoimmune, neurological, and psychiatric disorders. Age, sex ratio, ethnicity, HLA typing, karyotyping, disease course, frequency, and duration of KLS episodes did not differ between groups. Episodes were less frequent in familial versus sporadic KLS (2.3 ± 1.8/y versus 3.8 ± 3.7/y, P = 0.004). Menses triggered more frequently KLS onset in the nine girls with familial KLS (relative risk, RR = 4.12, P = 0.03), but not subsequent episodes. Familial cases had less disinhibited speech (RR = 3.44, P = 0.049), less combined hypophagia/hyperphagia (RR = 4.38, P = 0.006), more abrupt termination of episodes (RR = 1.45, P = 0.04) and less postepisode insomnia (RR = 2.16, P = 0.008). There was similar HLA DQB1 distribution in familial versus sporadic cases and no abnormal karyotypes.

**Conclusion:** Familial KLS is mostly present in the same generation, and is clinically similar to but slightly less severe than sporadic KLS.

**Keywords:** family, hypersomnia, Kleine-Levin syndrome, multiplex, periodic

**Citation:** Nguyen QT, Groos E, Leclair-Visonneau L, Monaca-Charley C, Rico T, Farber N, Mignot E, Arnulf I. Familial Kleine-Levin syndrome: a specific entity? *SLEEP* 2016;39(8):1535–1542.

### Significance

Kleine-Levin syndrome (KLS) is a rare disorder in adolescents, with relapsing-remitting episodes including hypersomnia, mental confusion, derealization, and apathy. The cause is unknown, but exceptional multiplex families have been reported. Here, for the first time, we measured among 260 patients with KLS that 8% had an affected family member. The disease was mostly present in the same generation. Familial KLS was clinically not different (although slightly less severe) from sporadic KLS, with similar HLA DQ distribution and no abnormal karyotypes. This large comparison of phenotype and genotype will support future DNA exome sequencing in these families and the role of genetics in KLS pathogenesis.

## INTRODUCTION


Kleine-Levin syndrome (KLS) is a rare neurological disorder (approximately two cases per million inhabitants) affecting mostly teenagers and young adults.<sup>1</sup> It is characterized by relapsing-remitting episodes of hypersomnia associated with behavioral, mood, and cognitive disturbances, such as confusion, apathy, and derealization. Less frequently, hyperphagia and hypersexuality are also observed during these episodes. The cause of KLS is unknown, in the absence of biological or imaging markers, except for decreased metabolism/perfusion in the associative cortex and the basal ganglia during episode in functional imaging.<sup>2</sup> An association of KLS with human leukocyte antigen (HLA) DQB1\*02 suggestive of autoimmune origin has been reported in an European series,<sup>3</sup> but not confirmed in two controlled series from the US<sup>4</sup> and France.<sup>5</sup> Most KLS cases are sporadic, but several multiplex families containing two to six cases have been described, including five families with two affected siblings (a set of twin brothers),<sup>6,7</sup> three with brother and sister,<sup>8–10</sup> a grandmother, a father and two children,<sup>11</sup> a mother and her son,<sup>3</sup> a father and his five children,<sup>12</sup> and an uncle and his nephew.<sup>13</sup> The report of several families for this exceptionally rare disorder suggests genetic vulnerability in some cases. Because large series containing familial cases are lacking, we systematically collected

demographic, clinical, and HLA measures in two large samples to compare sporadic and familial cases.

## METHODS

### Patients

Our study used the KLS database from the Stanford Center for Sleep Sciences and Medicine (Palo Alto, CA, USA) and from the National KLS Reference Center of Pitié-Salpêtrière hospital (Paris, France). All patient had signed an informed consent for clinical and genetic studies and the study was approved by ethic review boards of Stanford University and Pitié Salpêtrière Hospital, respectively. Patients used in this study were those consecutively enrolled from 2004 to 2005 in the Stanford Center, and from 2008 to 2015 in the Paris center. All patients met international criteria for primary KLS,<sup>14</sup> including: (1) episodes of hypersomnia lasting between 2 days and 4 w, occurring at least once per year, plus at least one of the following symptoms, including megaphagia, hypersexuality, abnormal behavior such as irritability, aggression or odd behavior, and cognitive abnormalities such as feeling of unreality, confusion and hallucination; (2) episodes recurring at least every year; (3) normal alertness, cognitive functioning, and behavior between attacks; and (4) with the disease being



not better explained by another sleep disorder, medical or neurological disorder, mental disorder, medication use, or substance use disorder. Note that all patients also met the more recent KLS criteria.<sup>15</sup> We did not include patients with atypical associated symptoms, differential and uncertain diagnoses, as well as secondary KLS, defined as the presence of neurological symptoms prior to the first KLS episode and persistent between episodes (Figure 1). A familial case was defined as any patient with KLS having at least one first- or second-degree relative affected with KLS and contrasted to sporadic cases (without any other affected family member, at first or second degree). A simplex family contained only one patient with KLS, and a multiplex family contained at least two patients with KLS, with a first- or second-degree family link.

### Investigations

A neurologist experienced in KLS diagnosis interviewed all patients. Subjects completed the Stanford KLS autoquestionnaire (whether in English or in French), which included 280 questions about personal and family history, onset and course of KLS, triggering factors, symptoms during episodes (sleep, cognition, derealization, eating and sexual behavior, psychiatric symptoms, autonomous nervous system symptoms), response to therapies and sleep, eating attitude, depression, and anxiety during asymptomatic periods.<sup>4,16</sup> Among the KLS autoquestionnaire questions, we combined the “childish speech,” “repetitive speech,” and “searching one’s words” questions into a single composite criterion named “poor speech.” Patients from Paris also completed the Starkstein Apathy scale, in and out of an episode.<sup>17</sup> All patients from the two centers had HLA genotyping, which included high-resolution DQB1 and DRB1 typing at Stanford and medium resolution typing of DQB1 in Paris, except for HLA DQB1\*06:02, which was looked for in all patients from the two centers. In addition, all French patients had a karyotype.

### Statistical Analysis

Measures are reported as mean  $\pm$  standard deviations or percentages whenever most appropriate. Dichotomous traits were analyzed using a chi-square test. Continuous variables were compared between groups using Student *t* tests. P values lower than 0.05 were considered as significant.

## RESULTS

### Frequency of Familial KLS

The initial sample included 279 patients referred for KLS, including 177 patients from Paris and 102 from Stanford (6 French patients common to the two centers were counted in the French center in which they were followed up). After review, 19 patients were excluded for unsure diagnosis ( $n = 7$ ),

atypical KLS ( $n = 7$ ), differential diagnosis ( $n = 4$ ; including bipolar disorder, atypical idiopathic hypersomnia, encephalopathy, Nieman-Pick Type C disease) and secondary KLS ( $n = 1$ , multiple sclerosis) leading to 260 typical patients. There were 239 patients with sporadic KLS and 21 patients with familial KLS from 10 multiplex families, yielding to 10 of 249 multiplex families (4%) and 21 of 260 familial (8%), of all cases. Family relationship included siblings ( $n = 12$ , including two pairs of monozygotic twins), parent-child ( $n = 4$ ), first-degree cousins ( $n = 2$ ), and uncle plus two nephews ( $n = 3$ ). All cases were born from nonconsanguineous parents. Family 4 and Family 9 were previously published.<sup>18,19</sup> The 10 family trees are shown in Figure 2. There were seven families with all affected cases in the same generation (siblings, same-generation cousins), two with vertical transmission (parent-child), and one with mixed different and same generations affected members (one uncle and his nephew and niece who were brother and sister). The frequency of familial cases was similar in both the French and USA series.

### Demography and Medical History

Ethnicities, sex ratio, mean age at KLS onset, and body mass index were not different between groups (Table 1). There was no difference in the frequency of psychiatric disorders, epilepsy, and neurodegenerative diseases in first-degree relatives, except for a trend toward more attention deficit among relatives of patients with familial versus sporadic KLS.

Prior reports of prematurity, difficulties at birth, and developmental difficulties were similar across groups. Age at puberty was similar in both groups. Patients with familial KLS tended to report allergy less frequently, but medical or sleep disorders occurred at the same frequency (Table 2). During asymptomatic periods, patients had normal apathy scores, eating behavior, anxiety and depression scores, and these were not different between familial and sporadic groups. Daytime

**Table 1**—Demography, ethnicity, familial history, human leukocyte antigen typing and karyotypes in familial versus sporadic Kleine-Levin syndrome.


KLS	Familial KLS (n = 21)	Sporadic KLS (n = 239)	P
Sex, male	12/21 (57.1)	169/239 (70.7)	0.19
Ethnicity (self-declared)			
Caucasian	19/21 (90.5)	218/239 (91.2)	0.36
Asian	0	1 (0.4)	0.10
Jewish	2/21 (9.5)	11 (4.6)	0.67
Arabic	0	3 (1.3)	0.53
African	0	4 (1.7)	0.69
Age at study entry, y	22.3 ± 9.5	24.5 ± 10.9	0.91
Laterality, % left-hander	2/19 (11.8)	35/221 (15.8)	0.65
Body mass index, kg/m <sup>2</sup>	24 ± 3	24 ± 5	0.96
Family history			
Depression	4/20 (20)	74/232 (31.9)	0.39
Bipolar disorder	0/12 (0)	3/138 (2.2)	0.49
Sleep disorder <sup>a</sup>	0/20 (0)	49/231 (21.2)	0.04
Epilepsy	3/20 (15)	33/233 (14.2)	0.82
Alzheimer disease	4/20 (20)	34/231 (14.7)	0.76
Attention deficit	3/20 (15)	9/233 (3.9)	0.09
HLA genotyping			
HLA DQ*02	13/40 (32.5)	90/416 (21.6)	0.12
HLA DQ*03	13/40 (32.5)	138/416 (33.2)	0.93
HLA DQ*04	1/40 (2.5)	10/416 (2.4)	0.62
HLA DQ*05	8/40 (20)	75/416 (18)	0.76
HLA DQ*06	5/40 (12.5)	103/416 (24.8)	0.08
HLA DQ*0602	2/40 (5)	42/416 (10.1)	0.45
Karyotype, abnormal	0/11 (0)	1/91 (1.1)	0.20

Data are presented as n (%) or mean ± standard deviation. Patients recruited at Stanford mostly came from the United States, and patients recruited in Paris came from France, Belgium, Swiss, United Kingdom and Germany. <sup>a</sup>Excluding KLS. HLA data were available from 20 patients in familial KLS and 208 patients in sporadic KLS. HLA, human leukocyte antigen; KLS, Kleine-Levin syndrome.

sleepiness (sleepiness score as well as naps frequency and duration) and the quality and quantity of nighttime sleep were also similar, although a trend for shorter sleep onset latency was reported in familial cases.

### Symptoms During KLS Episodes

As indicated in Table 3, 94% of familial and 87% of sporadic cases remembered an event prior to KLS onset (infection head trauma, alcohol intake, menarche) but the trigger involved was not different between groups, except that more frequent menses were reported before the



**Figure 2**—Family trees of patients with familial Kleine-Levin syndrome, including patients with Kleine-Levin syndrome diagnosed by the physician (plain black figures), subjects with possible Kleine-Levin syndrome as reported by families (plain gray figures), and subjects without Kleine-Levin syndrome (empty figures). Note that suspected cases reported by families are included on the pedigree but not included in the total count of 21 patients from KLS families.

**Table 2**—Medical history and asymptomatic periods in familial versus sporadic Kleine-Levin syndrome.

KLS	Familial KLS (n = 21)	Sporadic KLS (n = 239)	P
Medical history			
Prematurity	4/13 (30.8)	24/144 (16.7)	0.37
Difficult birth	3/21 (14.3)	56/239 (23.4)	0.49
Trouble in development	2/21 (9.5)	38/238 (16)	0.64
Age at puberty, y	12.3 ± 1.8	13.1 ± 1.4	0.13
Age at menarche, y	11.7 ± 1.8	12.8 ± 1.3	0.11
Migraines	1/20 (5.0)	45/224 (20.1)	0.18
Allergy	1/18 (5.6)	66/224 (29.5)	0.04
Epilepsy	2/21 (9.5)	14/232 (6.0)	0.87
Depression <sup>a</sup>	1/14 (7.1)	28/135 (20.7)	0.39
Sleepwalking	6/21 (28.6)	40/227 (17.6)	0.22
Night terrors	3/21 (14.3)	34/223 (15.2)	0.84
Nightmares	12/21 (57.1)	107/228 (46.9)	0.37
Sleep paralysis	2/18 (11.1)	20/211 (9.5)	0.84
Hypnagogic hallucinations	3/21 (14.3)	35/233 (15.0)	0.82
Asymptomatic periods			
Sleepiness score, 0–24	6 ± 4	5 ± 4	0.88
Eating behavior score, 0–37	8 ± 10	5 ± 6	0.19
Apathy score, 0–42 <sup>a</sup>	9 ± 2	9 ± 4	0.85
Anxiety and depression score, 0–42	9 ± 7	9 ± 6	0.72
Sleep well	20/20 (100)	203/231 (87.9)	0.20
Sleep onset before 23:00	13/21 (61.9)	129/232 (55.6)	0.58
Usual sleep time, min	474 ± 90	489 ± 84	0.49
Sleep latency, min	18 ± 11	25 ± 27	0.02
Difficulty to fall asleep	3/20 (15)	46/226 (20.4)	0.78
Naps	12/20 (60)	104/231 (45)	0.29
Number per week	1 ± 2	1 ± 2	0.39
Nap duration, min	54 ± 62	59 ± 63	0.78

Data are presented as n (%) or mean ± standard deviation. <sup>a</sup>Evaluated only in the Paris sample. KLS, Kleine-Levin syndrome.

**Table 3**—Events surrounding onset and disease course in patients with familial versus sporadic Kleine-Levin syndrome.

KLS	Familial KLS (n = 21)	Sporadic KLS (n = 239)	P
Age at KLS onset, y	15.5 ± 3.2	16.1 ± 4.9	0.42
Events surrounding KLS onset			
Infection	11/21 (52.4)	102/232 (44.0)	0.46
Stress	3/21 (14.3)	70/237 (29.5)	0.22
Alcohol	5/21 (23.8)	48/237 (20.3)	0.70
Drugs	2/21 (9.5)	25/237 (10.5)	0.82
Traveling	4/21 (19.0)	32/237 (13.5)	0.71
Menses	4/9 (44.4)	7/65 (10.8)	0.03
Head trauma	1/21 (5.3)	14/237 (5.9)	0.79
Vaccine	0/21 (0)	10/237 (4.2)	0.71
Frequency of episodes, n/y	2.3 ± 1.8	3.8 ± 3.7	0.004
Patients with episodes longer than 30 days	7/20 (35)	68/237 (28.7)	0.55
Mean episode duration, d	18 ± 25	13 ± 12	0.50
Decreased episode duration across time	5/8 (71.4)	34/113 (30.1)	0.13
Asymptomatic period duration, w	23 ± 18	18 ± 21	0.38
Decreased performance at school/work	8/17 (47.1)	118/216 (54.6)	0.55

Data are presented as n (%) or mean ± standard deviation. KLS, Kleine-Levin syndrome.

**Table 4**—Symptoms during episodes of Kleine-Levin syndrome.

KLS	Familial KLS (n = 21)	Sporadic KLS (n = 239)	P
Sleep			
Difficult awakening	15/19 (78.9)	188/228 (82.5)	0.94
Intense dreaming	12/15 (80)	130/194 (67)	0.45
Problem speaking	16/20 (80)	217/237 (91.6)	0.19
Mute	8/19 (42.1)	97/237 (40.9)	0.92
Slow speech	12/21 (57.1)	178/237 (75.1)	0.07
Poor speech <sup>a</sup>	15/21 (71.4)	200/237 (84.4)	0.13
Disinhibited speech <sup>b</sup>	2/21 (9.5)	78/238 (32.8)	0.049
Mental confusion	15/18 (83.3)	209/232 (90.1)	0.61
Lost in time	18/18 (83.3)	202/225 (89.8)	0.65
Lost in space	9/17 (52.9)	111/198 (56.1)	0.80
Reduced attention	17/19 (89.5)	227/232 (97.8)	0.16
Derealization	19/20 (95)	225/236 (95.3)	0.63
Behavioral disturbances	20/21 (95.2)	232/239 (97.1)	0.85
Irritability	10/21 (47.6)	151/239 (63.2)	0.16
Apathy	16/21 (76.2)	180/239 (75.3)	0.86
Apathy score, 0–42 <sup>c</sup>	28 ± 9	32 ± 7	0.34
Disinhibition	9/21 (42.9)	157/239 (65.7)	0.06
Stereotypies	4/10 (40)	29/95 (30.5)	0.80
Autonomous problems	17/21 (81)	208/237 (87.8)	0.58
Eating behavior disturbance	19/21 (90.5)	229/239 (95.8)	0.56
Increased appetite	8/21 (38.1)	103/239 (43.1)	0.66
Megaphagia	12/21 (57.1)	106/239 (44.4)	0.26
Decreased appetite	9/21 (42.9)	94/239 (39.3)	0.75
Increased/Decreased appetite <sup>d</sup>	5/21 (23.8)	13/239 (5.4)	0.006
Sexual disturbance	11/21 (52.4)	125/234 (53.4)	0.93
Hypersexuality	10/21 (47.6)	84/232 (36.2)	0.30
Sexual disinhibition	4/21 (19)	51/232 (22)	0.97
Decreased sexuality	0/21 (0)	19/232 (8.2)	0.35
Hyper/hyposexuality (mixed)	0/21 (0)	5/232 (2.2)	0.89
Psychiatric disturbances	18/20 (90)	209/237 (88.2)	0.90
Hallucination	7/21 (33.3)	103/231 (44.6)	0.32
Delusion	6/20 (30)	79/237 (33.3)	0.76
Depression	13/20 (65)	140/237 (59.1)	0.78
Anxiety	9/20 (45)	112/236 (47.5)	0.83
End of episodes			
Frequent insomnia	7/20 (35)	115/234 (49.1)	0.22
No insomnia	10/20 (50)	54/233 (23.2)	0.008
Abrupt termination (over hours)	3/20 (15)	94/227 (41.4)	0.038
Amnesia of episode	15/20 (75)	176/233 (75.5)	0.83

Data are presented as n (%) or mean ± standard deviation. <sup>a</sup>Poor speech included childish, repetitive or slurred speech and “searching words.” <sup>b</sup>Desinhibited speech included “repetitive speech” and “inappropriate speech.” <sup>c</sup>In patients from Paris only. <sup>d</sup>Presence of episodes with decreased appetite and of episodes with increased appetite in the same patient. KLS, Kleine-Levin syndrome.

first episode in women with familial versus sporadic KLS (relative risk = 4.13). Menses and other triggering factors were equally associated with KLS relapses in both groups, however. Age at KLS onset and first, longest, shortest, and mean episode durations were similar between groups. The frequency of episodes was lower in patients with familial versus sporadic KLS. Notably, the patients with familial KLS experienced most episodes at different times from their siblings.

On average, the longest (21 h) and shortest (14–16 h) sleep durations during episodes were similar between groups (data not shown), as well as reports of intense dreaming, difficulties to be awakened, and sleep paralysis. As for cognitive symptoms, sporadic patients had more disinhibited language (relative risk = 3.44) and tended to have a slower language delivery than in the familial group, but the frequency of confusion, attention problems, and derealization was equally high

**Table 5**—HLA DQB1 genotypes in patients with familial Kleine-Levin syndrome in our study (families with numbers) and in the scientific literature (families with letters).

Family Number	Member 1	Member 2	Other Members	Family Link	Reference
Family one	DQB1* <u>201</u> , 501	DQB1* <u>201</u> , 303	None	Father-child	Nguyen et al., 2016
Family two	DQB1* <u>202</u> , <u>301</u>	DQB1* <u>202</u> , <u>301</u>	None	Siblings	Nguyen et al., 2016
Family three	DQB1*02, 203	MD	None	Siblings	Nguyen et al., 2016
Family four	DQB1*402, <u>601</u>	DQB1*301, <u>601</u>	None	Siblings	Katz et al., 2002
Family five	DQB1* <u>03</u> , <u>03</u>	DQB1* <u>03</u> , <u>03</u>	None	Siblings	Nguyen et al., 2016
Family six	DQB1* <u>503</u> , 501	DQB1* <u>503</u> , 602	None	Father-child	Nguyen et al., 2016
Family seven	DQB1* <u>02</u> , <u>05</u>	DQB1* <u>02</u> , <u>05</u>	None	Monozygotic twins	Nguyen et al., 2016
Family eight	DQB1* <u>02</u> , <u>03</u>	DQB1* <u>02</u> , <u>03</u>	None	Monozygotic twins	Nguyen et al., 2016
Family nine	DQB1*201, 501	DQB1*03, 06	None	First-degree cousins	Janicki et al., 2001
Family ten	DQB1* <u>02</u> , 05	DQB1* <u>02</u> , 03	DQB1* <u>02</u> , 0602	Uncle-nephews	Nguyen et al., 2016
Family A	MD	MD	None	Siblings	Bonkalo, 1968
Family B	MD	MD	MD	Grandmother-father-children	Suwa and Toru, 1969
Family C	DQB1* <u>0201</u> , <u>201</u>	DQB1* <u>0201</u> , <u>201</u>	None	Mother-child	Dauvilliers et al., 2002
Family D	MD	MD	None	Uncle-nephew	Poppe et al., 2003
Family E	DQB1*501, 604	MD	None	Siblings	Beudin et al., 2006
Family F	DQB1* <u>02</u> , <u>06</u> <sup>a</sup>	DQB1* <u>02</u> , <u>02</u>	DQB1* <u>02</u> , <u>02</u>	Father-5 children	Bahamman et al., 2008
Family G	DQB1* <u>303</u> , <u>501</u>	DQB1* <u>303</u> , <u>501</u>	None	Siblings	Rocamora et al., 2010
Family H	MD	MD	None	Monozygotic twins	Ueno et al., 2012
Family I	DQB1* <u>0302</u> , <u>0601</u>	DQB1* <u>0302</u> , <u>0601</u>	None	Monozygotic twins	Peraita et al., 2012

<sup>a</sup> Four affected and two nonaffected members were DQB1\*02 homozygote. Genotypes common to two affected members are underlined. MD, missing data.

in both groups (Table 4). As for behavioral problems, the frequency and severity of apathy as well as the frequency of irritability were similar in both groups, but patients with familial KLS tended to have less sexual disinhibition and had more frequently both increased and/or decreased appetite depending upon episodes (relative risk = 4.38), in contrast with more frequent single kinds of appetite change (eating less or eating more) in patients with sporadic KLS. Psychiatric and autonomous nervous system problems were equally frequent and similar between groups. At the end of episodes, patients with sporadic KLS had more frequently insomnia (relative risk = 1.54), a more rapid termination of episodes (relative risk = 2.76), but a similar degree of retrograde amnesia when compared to familial cases.

#### Human Leukocytes Class II Antigens, Karyotypes, and Brain Functional Imaging

Frequency and distribution of HLA DQ alleles did not differ between familial and sporadic groups (Table 1). Karyotyping was normal in all patients except for a patient with sporadic KLS who had 1.61Mb duplication in Xp22.31 (containing four genes HDHD1, STS, VCX, and PNPLA4). Quantitative polymerase chain reaction confirmed this duplication, which was inherited from his mother (who had no KLS or other neurological and psychiatric disorders). This patient had developmental delay (toiletting, language), attention deficit, childhood anxiety, and mild autistic spectrum disorder. The twin sisters (Family 7) and the nontwin sisters (Family 5) both had a similar decreased metabolism in the left temporo-occipital junction in positron emitting tomography with fluorodeoxyglucose during the asymptomatic period. This decreased metabolism in temporo-occipital

junction was a common finding during asymptomatic periods in approximately two-thirds of sporadic cases here.

#### DISCUSSION

In this large joint series of patients with KLS from the US and France, 8% of cases were familial (4% of multiplex families), with two to three cases observed in the same multiplex family. Familial and sporadic cases shared a very similar demographic, clinical, and biological profile. During asymptomatic periods, nothing distinguished familial from sporadic cases. However, the frequency of episodes was lower in patients with familial KLS. Menses preceded more frequently the first KLS episode in girls with familial than sporadic KLS. Several symptoms were less marked in familial than in sporadic cases, including less frequent disinhibited language, as well as more mixed (increased/decreased appetite) eating disorders, and a more progressive termination of episodes, with less frequent postepisode insomnia. This blunted symptomatology may be related to differences in recruitment, as severe index cases are most likely to come to the attention of our center whereas systematic screening of the family cases will identify even milder cases. Nonetheless, symptoms were very similar between index cases and other affected family members including core symptoms of KLS (hypersomnia, derealization, apathy, cognitive problems) and the less frequent associated disinhibited behaviors (megaphagia, hypersexuality) and psychiatric symptoms (delusion, hallucination, depression) symptoms. Similarly, genetic markers (including HLA genotyping and karyotypes) were also similar between groups when tested.

The frequency of familial KLS had been previously evaluated in a series of 120 patients, and estimated at 5% of patients

or 1.7% of family members.<sup>4</sup> With a prevalence of 2 to 10 patients with KLS per million of inhabitants and five first-degree relatives per proband, we previously estimated an 800- to 4,000-fold increased risk in first-degree relatives. With the new estimate including 21 patients from 10 families among 260 patients, a similar 1,300-fold (800- to 4,000-fold) increased risk in first-degree relatives was calculated. This increase occurred without any evidence of consanguinity or without any differences in ethnicity. Most notably, no relative increase of Jewish origin among French patients with KLS was observed,<sup>5</sup> unlike in American patients,<sup>4</sup> but as most patients were Caucasians, estimation of familial risk in other ethnicities was not possible. The familial cases were mostly (70%) belonging to the same generation in our series, as for seven of nine previously published cases (78%, Table 5). The low vertical risk must be stressed, as it is useful to reassure KLS patients with regard to their children.

The more frequent association of KLS onset with menses in familial cases suggests a possible link between female hormones and familial KLS. Sporadic KLS syndrome is noteworthy male predominant (68% to 87%).<sup>1</sup> Female cases with episode onset linked to menstruation have been reported by Kleine,<sup>20</sup> and later singled out as a distinct syndrome, menstrual-related hypersomnia.<sup>21</sup> Because patients have similar symptoms (hypersomnia, megaphagia, mood disorders, hypersexuality) as classic KLS,<sup>22</sup> the disorder is now considered as a variant form of KLS in most recent classifications of sleep disorders.<sup>15</sup> In menstrual-related hypersomnia, relapses are always or almost always associated with menses and/or puerperium, which was not the case in our female patients with familial KLS. It should be noted that other hormone-dependent factors, including menarche and age at puberty, did not differ between familial versus sporadic KLS.

The pathophysiology of KLS is unknown. An autoimmune origin has been suspected, because KLS affects mostly young people, is relapsing-remitting, and is often triggered by unspecific infections at KLS onset and during relapses.<sup>23</sup> Narcolepsy type 1, another sleep disorder of autoimmune origin, is strongly associated with HLA DQB1\*06:02 and can be triggered by infections (streptococcus and H1N1 influenza) but more rarely familial than KLS.<sup>24</sup> In KLS, the DRB1\*0301–DQB1\*0201 and DRB1\*0701–DQB1\*0202 haplotypes (when grouped together) were more often encountered in 30 European patients with KLS than in controls,<sup>3</sup> but this result was not confirmed in several subsequent larger series from the US,<sup>4</sup> France,<sup>5</sup> and Taiwan.<sup>23</sup> In this study, no specific HLA DQ association was found in familial KLS either. Although familial clustering was observed, the 11 French familial cases had no common karyotype abnormality, suggesting that familial KLS does not result from any large common chromosomal alteration. Interestingly, however, one patient presented with a micro-duplication of Xp22.31 (inherited from his otherwise healthy mother) but he had sporadic KLS. This duplication has been reported as a possible cause of intellectual disability, behavior abnormalities (autism), hypotonia, and seizures.<sup>25</sup> Genes in the duplicated area include HDHD1, VCX, STS (steroid sulfatase, deficient in X-linked ichthyosis), and PNPLA4. High- definition karyotype and DNA exome sequencing are next needed to explore

whether more subtle DNA abnormalities can be found in the multiplex KLS families.

## REFERENCES

1. Arnulf I, Rico T, Mignot E. Diagnosis, disease course, and management of patients with Kleine-Levin syndrome. *Lancet Neurol* 2012;11:918–28.
2. Kas A, Lavault S, Habert MO, Arnulf I. Feeling unreal: a functional imaging study in 41 patients with Kleine-Levin syndrome. *Brain* 2014;137:2077–87.
3. Dauvilliers Y, Mayer G, Lecendreux M, et al. Kleine-Levin syndrome: an autoimmune hypothesis based on clinical and genetic analyses. *Neurology* 2002;59:1739–45.
4. Arnulf I, Lin L, Gadoth N, et al. Kleine-Levin syndrome: a systematic study of 108 patients. *Ann Neurol* 2008;63:482–93.
5. Lavault S, Golmard J, Groos E, et al. Kleine-Levin syndrome in 120 patients: differential diagnosis and long episodes. *Ann Neurol* 2015;77:529–40.
6. Ueno T, Fukuhara A, Ikegami A, Ohishi F, Kume K. Monozygotic twins concordant for Kleine-Levin syndrome. *BMC Neurol* 2012;12:31.
7. Peraita-Adrados R, Vicario JL, Tafti M, Garcia de Leon M, Billiard M. Monozygotic twins affected with kleine-levin syndrome. *Sleep* 2012;35:595–6.
8. Bonkalo A. Hypersomnia. A discussion of psychiatric implications based on three cases. *Br J Psychiatry* 1968;114:69–75.
9. Beudin P. Un syndrome de Kleine-Levin : une histoire familiale. *Med Som* 2006;3:55–6.
10. Rocamora R, Gil-Nagel A, Franch O, Vela-Bueno A. Familial recurrent hypersomnia: two siblings with Kleine-Levin syndrome and menstrual-related hypersomnia. *J Child Neurol* 2010;25:1408–10.
11. Suwa K, Toru M. A case of periodic somnolence whose sleep was induced by glucose. *Folia Psychiatr Neurol Jpn* 1969;23:253–62.
12. Bahammam A, Gadelrab M, Owais S, Alswat K, Hamam K. Clinical characteristics and HLA typing of a family with Kleine-Levin syndrome. *Sleep Med* 2008;9:575–8.
13. Poppe M, Friebe D, Reuner U, Todt H, Koch R, Heubner G. The Kleine-Levin syndrome - effects of treatment with lithium. *Neuropediatrics* 2003;34:113–9.
14. American Academy of Sleep Medicine. *International Classification of Sleep Disorders*, 2nd ed. Westchester, IL: American Academy of Sleep Medicine, 2005.
15. American Academy of Sleep Medicine. *International Classification of Sleep Disorders*, 3rd ed. Darien, IL: American Academy of Sleep Medicine, 2014.
16. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatrica Scandinavica* 1983;67:361–70.
17. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. *J Neuropsychiatry Clin Neurosci* 1992;4:134–9.
18. Katz JD, Ropper AH. Familial Kleine-Levin syndrome: two siblings with unusually long hypersomnic spells. *Arch Neurol* 2002;59:1959–61.
19. Janicki S, Franco K, Zarko R. A case report of Kleine-Levin syndrome in an adolescent girl. *Psychosomatics* 2001;42:350–2.
20. Kleine W. Periodische Schlafsucht. *Monatsschrift für Psychiatrie und Neurologie* 1925;57:285–320.
21. Billiard M, Guilleminault C, Dement WC. A menstruation-linked periodic hypersomnia. Kleine-Levin syndrome or new clinical entity? *Neurology* 1975;25:436–43.
22. Billiard M, Jaussent I, Dauvilliers Y, Besset A. Recurrent hypersomnia: a review of 339 cases. *Sleep Med Rev* 2011;15:247–57.
23. Huang Y, Guilleminault C, Lin K, Hwang F, Liu F, Kung Y. Relationship between Kleine-Levin Syndrome and upper respiratory infection in Taiwan. *Sleep* 2012;35:123–9.
24. Mignot E. Genetic and familial aspects of narcolepsy. *Neurology* 1998;50:S16–22.

25. Li F, Shen Y, Köhler U, et al. Interstitial microduplication of Xp22.31: Causative of intellectual disability or benign copy number variant? *Eur J Med Genet* 2010;53:93–9.

## ACKNOWLEDGMENTS

The authors thank the physicians who referred their patients for suspicion of KLS. Authors' contribution: Dr. Nguyen collected the clinical information in a database, performed the statistics and prepared, with Dr. Arnulf, the first manuscript draft. Dr. Groos helped diagnosing patients with KLS and ruled out psychiatric diagnoses. Dr. Leclair-Visonneau and Dr. Monaca diagnosed and referred more than five patients with KLS via the Rare Disease network. Mr. Rico and Mr. Farber recruited patients in USA. Dr. Mignot obtained the grant for collecting the USA KLS cohort and edited the manuscript. Dr. Arnulf obtained the grant for collecting the French patients cohort, diagnosed and collected the Stanford patients, diagnosed, treated, and followed up the French KLS patients (helped by Dr. Groos), and drafted the manuscript. The final manuscript was approved by all coauthors.

## SUBMISSION & CORRESPONDENCE INFORMATION

Submitted for publication March, 2016

Submitted in final revised form April, 2016

Accepted for publication April, 2016

Address correspondence to: Isabelle Arnulf, Service des pathologies du sommeil, Hôpital Pitié Salpêtrière, 47-83 boulevard de l'Hôpital, 75651 Paris Cedex 13; Tel: 33 (0) 1 42167702; Fax: 33 (0) 1 42167700; Email: [isabelle.arnulf@aphp.fr](mailto:isabelle.arnulf@aphp.fr)

## DISCLOSURE STATEMENT

This was not an industry-supported study. The French Kleine-Levin syndrome research program was funded in part by a grant to Dr. Arnulf (PHRC 070138) from the French Ministry of Health. It was sponsored by the Assistance Publique - Hôpitaux de Paris. The American cohort was initiated thanks to a grant from the Kleine-Levin Syndrome Foundation (Boston). Outside this work, Dr. Arnulf received honoraria for board and speaking engagements from UCB Pharma, and reported another study on brain imaging in KLS founded by the KLS Foundation in Boston. Dr. Leclair-Visonneau and Prof. Monaca had travels and congresses paid by UCB Pharma. Dr. Mignot received a grant from the Kleine-Levin syndrome foundation (Boston) to start the KLS clinical and DNA collection. Outside this work, Dr. Mignot received funding and occasional consulting income from Jazz Pharmaceuticals, had a grant from The Lundbeck Foundation, Sunovion and GSK, was consultant for Novo Nordisk, Resmet, Merk, Resmed and INC, developed a device with ALPCO, and was speaker's bureau for the Federal Trade Commission. The other authors have indicated no financial conflicts of interest.